Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.…
PLX: Elfabrio Estimates Up, Again
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
Protalix BioTherapeutics (NYSEAMERICAN: PLX) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 226 employees.
The shares were at 2.900 USD on 20 November 2026, up 32.4% over 52 weeks. Its 52-week range is 1.650 USD to 3.190 USD: the price is 9.1% below the high and 75.8% above the low.
At a market capitalisation of 244.52M USD, it trades at 12.1 times trailing earnings and 4.7 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 64% for PLX.
Protalix BioTherapeutics reports return on equity of -13.7%, an operating margin of 29.8% and revenue up 22.8% year over year.
It holds more cash than debt, a net cash position of 39.39M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.